Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study

Ying Zhao,Tamaryn Fox,Kathryn Manning,Annemie Stewart,Nicki Tiffin,Ntokozo Khomo,Joshua Leslie,Andrew Boulle,Vanessa Mudaly,Yulene Kock,Graeme Meintjes,Sean Wasserman

Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study

2019

Ying Zhao
Tamaryn Fox
Kathryn Manning
Annemie Stewart
Nicki Tiffin
Ntokozo Khomo
Joshua Leslie
Andrew Boulle
Vanessa Mudaly
Yulene Kock
Graeme Meintjes
Sean Wasserman

Background Bedaquiline is used as a substitute for second-line injectable (SLI) intolerance in the treatment of multidrug-resistant (MDR) tuberculosis, but the efficacy and safety of this strategy is unknown.

Keywords:

Bedaquiline
Immunology
Intensive care medicine
Multiple drug resistance
Tuberculosis
Retrospective cohort study
Medicine
Culture conversion
Confidence interval
Odds ratio
Mortality rate
Internal medicine
Relative risk

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations